XML 43 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1

Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues:
Total	$ 23,562	$ 11,812	$ 57,615	$ 23,490
Recognition of Upfront Fee [Member]
Revenues:
Total	23,538	11,759	57,378	23,042
Kite Pharma, Inc. ("Kite") [Member]
Revenues:
Total	9,028		16,544
Kite Pharma, Inc. ("Kite") [Member] | Recognition of Upfront Fee [Member]
Revenues:
Total	6,296		12,249
Kite Pharma, Inc. ("Kite") [Member] | Research Services [Member]
Revenues:
Total	2,732		4,295
Pfizer Collaboration for SB-525 | Recognition of Upfront Fee [Member]
Revenues:
Total	10,421	6,624	26,262	10,384
Bioverativ Inc [Member]
Revenues:
Total	2,240	3,401	11,139	9,062
Bioverativ Inc [Member] | Recognition of Upfront Fee [Member]
Revenues:
Total	1,094	442	3,432	1,326
Bioverativ Inc [Member] | Research Services [Member]
Revenues:
Total	$ 1,146	2,959	$ 7,707	7,736
Shire AG [Member]
Revenues:
Total		1,172		2,449
Shire AG [Member] | Recognition of Upfront Fee [Member]
Revenues:
Total		1,166		2,333
Shire AG [Member] | Research Services [Member]
Revenues:
Total		$ 6		$ 116

X

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenuesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=sgmo_ResearchServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=sgmo_PfizerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=sgmo_BioverativIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=sgmo_ShireAgMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: